Oxaliplatin Liposome Stabilization via MES Buffering
Solution Overview
Problem
Current methods for stabilizing oxaliplatin-encapsulating liposome aqueous dispersions fail to provide long-term storage stability, leading to degradation of phospholipids and reduced pharmacological effects due to pH fluctuations and incompatibility with oxaliplatin.
Innovation Solution
Incorporating 2-morpholinoethanesulfonic acid (MES) as a stabilizer in the external aqueous phase of liposomes, maintaining a pH of 5 to 8, and using saturated phospholipids like hydrogenated purified soybean phosphatidylcholines, to stabilize the liposome dispersion and prevent oxaliplatin degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional stabilizers (citric acid, tartaric acid, histidine, taurine, or tris) are used to stabilize liposome aqueous dispersions, then pH change and phospholipid hydrolysis are reduced, but oxaliplatin compatibility is poor and long-term storage stability is not achieved
Solution Approach 1:
The patent changes the chemical parameter of the stabilizer from conventional options (citric acid, tartaric acid, histidine, taurine, or tris) to 2-morpholinoethanesulfonic acid (MES). This parameter change resolves the contradiction by providing a stabilizer that simultaneously achieves long-term storage stability and compatibility with oxaliplatin, eliminating the trade-off between reliability and adaptability.
2Reliability
If oxaliplatin is encapsulated in liposomes, then antitumor activity is enhanced and toxicity is reduced, but phospholipid degradation occurs and pH reduction accelerates hydrolysis
Solution Approach 1:
The patent introduces MES as an intermediary substance in the external aqueous phase that mediates between oxaliplatin and phospholipids. MES buffers pH changes caused by oxaliplatin degradation and phospholipid hydrolysis, preventing the negative feedback loop where pH reduction accelerates hydrolysis. This intermediary作用 maintains phospholipid stability while preserving the antitumor efficacy of encapsulated oxaliplatin.
3Duration of action of stationary object
If liposome aqueous dispersion is stored long-term, then pharmacological effects are maintained, but pH reduction and phospholipid hydrolysis occur
Solution Approach 1:
The patent applies preliminary action by adding MES as a stabilizer to the external aqueous phase before storage. This preliminary stabilization prevents pH reduction and phospholipid hydrolysis during long-term storage, allowing the liposome aqueous dispersion to maintain its chemical stability and pharmacological effects over extended periods without degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in an oxaliplatin-encapsulating liposome aqueous dispersion with excellent long-term storage stability, maintaining stability even at high temperatures and reducing degradation of both oxaliplatin and phospholipids, thereby enhancing antitumor activity while minimizing side effects.
Implementation Method 1
Incorporating 2-morpholinoethanesulfonic acid (MES) as a stabilizer in the external aqueous phase of liposomes, maintaining a pH of 5 to 8
Implementation Method 2
The liposome is a closed endoplasmic reticulum formed of a bilayer membrane with hydrophobic groups of phospholipids facing each other
Implementation Method 3
oxaliplatin, which has a high rate of binding to plasma proteins and hemocytes, and which is prone to distribution in normal tissues
Data Source
AI summary
An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.